Developing Natural Solutions for Human Health®
Aphios is advancing differentiated therapeutics for oncology supportive care,
neurodegenerative and central nervous system disorders, addiction, and
infectious diseases by integrating pharmaceutical development with proprietary
natural-product discovery, manufacturing, purification, and nanotechnology
drug-delivery platforms.
Zindol®
Phase 3-ready therapy for chemotherapy-induced nausea and vomiting
Zindol® is Aphios’ most advanced therapeutic candidate and is being developed
for the prevention and treatment of chemotherapy-induced nausea and vomiting
(CINV), an important supportive-care need for patients receiving cancer therapy.
The program has completed prior Phase II/III clinical evaluation and is being
advanced toward pivotal development. Aphios is pursuing strategic and regional
partnerships to support clinical development and commercialization in major
global markets.
Phase 3-ready
Oncology Supportive Care
Global Partnering Opportunity
Additional Therapeutic Programs
Aphios is building a diversified therapeutic pipeline across neurodegeneration,
addiction, neuropsychiatry, and infectious disease by combining differentiated
drug candidates with proprietary enabling technologies.
Alzheimer’s Disease & CNS Disorders
Aphios is developing nanotechnology-enabled therapeutics designed to
improve delivery and pharmacological performance in Alzheimer’s disease,
neuroinflammation, pain, and related CNS disorders.
Programs include:
APH-1104 — Nano Bryostatin-22
APH-1105 — Nano Bryostatin-1
APH-2502 — CCR5 antagonist
Extended-Release Therapeutics
Aphios Pharma is developing proprietary extended-release formulations
designed to address treatment adherence, pharmacokinetic variability,
and relapse prevention.
Lead program:
APH-1501 — extended-release cannabidiol plus low-dose naltrexone
for opioid use disorder.
Natural-Product Anti-Infectives
Aphios applies its marine natural-products discovery capabilities
and enabling technologies to identify and develop differentiated
therapies against infectious diseases.
Programs include:
Bryolat™ — HIV-1 latency strategy
Antiviral and antimicrobial discovery programs
Natural diversity enabled by proprietary science
Aphios sources biologically active compounds from marine and terrestrial
organisms and applies proprietary extraction, purification, formulation,
and drug-delivery technologies to transform promising natural compounds
into differentiated therapeutic candidates.
Enabling Technology Platforms
- SFS-CXF™ extraction and fractionation
- SFS-CXP™ purification
- PNS™ polymer nanoparticle drug delivery
- SFS-CFN™ nanosome formulation
- CFI® pathogen-reduction technology
From Discovery Through Development
Aphios combines proprietary enabling technologies with internal drug-development
capabilities and strategic collaborations to advance promising therapeutic
candidates toward clinical development and commercialization.
Partnering for the future of human health®
Aphios seeks strategic partners for clinical development, regional and global
commercialization, licensing, co-development, and application of our proprietary
enabling technologies to partner compounds.
Research Chemicals, APIs & Equipment
Aphios also provides
Research Chemicals & APIs
for research, drug discovery, standards, pharmaceuticals and related applications,
as well as custom-designed
equipment
supporting drug discovery, pharmaceutical manufacturing, drug delivery and
pathogen safety.